A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children

British Journal of Cancer

Volumn 77, Issue 12, 1998, Pages 2318-2323

  Lowis, S P ^a,b,d   Price, L ^a   Pearson, A D J ^a   Newell, D R ^b   Cole, M ^a,c  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Adaptive dosing; Children; Etoposide; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC ALKALOID; ETOPOSIDE;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; PLASMA CLEARANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0031775809     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.385     Document Type: Article

References (23)

1. Aisner J, Van Echo DA, Whitacre M and Wiernik PH (1982) A phase I trial of continuous infusion VP16-213 (Etoposide). Cancer Chemother Pharmacol 7: 157-160
2. Bennett CL Sinkule JA, Schilsky RL, Senekjan EA and Choi KE (1987) Phase I clinical and pharmacological study of 72 hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47: 1952-1956
3. Boos J, Krumpelmann S, Schulze-Westhoff P, Euting T, Berthold F, Jurgens H (1995) Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol 13: 2954-2950
4. D'Argenio DZ and Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Progr Biomed 9: 115-134
5. English MW, Lowis SP, Peng B, Pearson ADJ, Newell DR, Craft AW (1996) Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis. Br J Cancer 73: 776-780
6. Fukuoka M, Masuda N, Negoro S, Takada M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Tachikawa A and Kawahara M (1991) A phase I study of chronic daily oral etoposide in combination with cisplatin for patients with advanced cancer. Cancer 68: 284-288
7. Gentili D, Zucchetti M, Torri V, Sessa C, de Jong J, Cavalli F and D'Incalci M (1993) A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemother Pharmacol 32: 482-486
8. Henwood JM and Brogden RN (1990) Etoposide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39: 438-490
9. Joel SP, Heap L, Robbins S, Clarke PI and Slevin ML (1990) A limited sampling strategy for the calculation of etoposide pharmacokinetics. Proc Am Soc Clin Oncol 9: 67
10. Joel SP, Ellis P, O'Byrne K, Papamichael D, Hall M, Penson R, Nicholls S, O'Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D and Slevin M (1996) Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. J Clin Oncol 14: 1903-1912
11. Kunitah H and Watanabe K (1994) Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 12: 83-89
12. Lokich J and Corkery J (1981) Phase I study of VP-16-213 (etoposid) administered as a continuous 5 day infusion. Cancer Treat Rep 65: 887-889
13. Lokich J, Anderson N, Bern M, Wallach S, Moore C and Williams D (1989) Etoposide admixed with cisplatin. Phase I clinical investigation of 72 hour infusion. Cancer 63: 818-821
14. Lowis SP, Pearson ADJ, Newell DR and Cole M (1993) Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 53: 4881-4889
15. Miller AA and Tolley EA (1994) Predictive performance of a pharmacodynamic model for oral etoposide. Cancer Res 54: 2080-2083
16. Minami H, Shimokata K, Saka H, Saito H, Ando Y, Senda K, Nomura F and Sakai S (1993) Phase I clinical and pharmacokinetic study of 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 11: 1602-1608
17. Pflüger K-H, Schmidt L, Merkel M, Jungclas H and Havermann K (1987) Drug monitoring of etoposide (VP16-213). Cancer Chemother Pharmacol 20: 59-60
18. Pflüger K-H, Hahn M, Hoz J-B, Schmidt L, Kohl P, Fritsch H-W, Jungclas H and Havermann K (1993) Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 31: 350-356
19. Ratain MJ, Schilsky RL, Choi KE, Guarnieri C, Grimmer D, Vogelzang NJ, Senekjian E and Liebner MA (1989) Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 45: 226-233
20. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ and Berezin F (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9: 1480-1486
21. Relling MV, McLeod HL, Bowman LC and Santana VM (1994) Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to etoposide. Clin Pharmacol Ther 56: 503-511
22. Sheiner LB and Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinetics Biopharmaceutics 9: 503-512
23. Strömgren AS, Sörensen BT, Jakobsen P and Jakobsen A (1993) A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 32: 226-230